True versus mild hyperthermia during isolated hepatic perfusion: Effects on melphalan pharmacokinetics and liver function

World Journal of Surgery

Volumn 28, Issue 8, 2004, Pages 775-781

  Pilati, Pierluigi ^a   Mocellin, Simone ^a   Rossi, Carlo R ^a   Ori, Carlo ^a   Innocente, Federico ^a   Scalerta, Romano ^a   Ceccherini, Mauro ^a   Da Pian, Pier Paolo ^a   Nitti, Donato ^a   Lise, Mario ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN TC 99M; AMINOTRANSFERASE; BILIRUBIN; INDOCYANINE GREEN; MELPHALAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; DRUG EFFECT; GAS CHROMATOGRAPHY; HYPERTHERMIC THERAPY; ISOLATED HEPATIC PERFUSION; LIVER BIOPSY; LIVER FUNCTION; LIVER PERFUSION; LIVER SCINTISCANNING; LIVER TUMOR; MASS SPECTROMETRY; NONHUMAN; SWINE;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; FEASIBILITY STUDIES; HEPATITIS, TOXIC; HEPATOCYTES; HYPERTHERMIA, INDUCED; LIVER; LIVER FUNCTION TESTS; MELPHALAN; RADIONUCLIDE IMAGING; SWINE; TECHNETIUM TC 99M AGGREGATED ALBUMIN; TEMPERATURE;

EID: 4744363413     PISSN: 03642313     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00268-004-7430-4     Document Type: Article

References (41)

1. Ragnhammar P, Hafstrom L, Nygren P, et al. A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol. 2001;40:282-308
2. Rossi CR, Foletto M, Pilati P, et al. Isolated limb perfusion in locally advanced cutaneous melanoma. Semin. Oncol. 2002;29:400-409
3. Eggermont AM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas: the cumulative multicenter European experience. Ann. Surg. 1996;224:756-764
4. Christoforidis D, Martinet O, Lejeune FJ, et al. Isolated liver perfusion for non-resectable liver tumours: a review. Eur. J. Surg. Oncol. 2002;28:875-890
5. Kemeny N, Seiter K, Conti JA, et al. Hepatic arterial floxuridine and leucovorin for unresectable liver metastases from colorectal carcinoma. New dose schedules and survival update. Cancer 1994;73:1134-1142
6. Nitti D, Da Pian P, Pilati P, et al. Hepatic arterial infusion (HAI) for unresectable liver metastases (ULM) from colorectal carcinoma. Tumori 1997;83:61
7. Venook AP. Update on hepatic intra-arterial chemotherapy. Oncology Huntingt. 1997;11:947-957
8. Kemeny N, Conti JA, Cohen A, et al. Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma. J. Clin. Oncol. 1994;12:2288-2295
9. Rougier P, Laplanche A, Huguier M, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J. Clin. Oncol. 1992;10:1112-1118
10. Kath R, Hayungs J, Bornfeld N, et al. Prognosis and treatment of disseminated uveal melanoma. Cancer 1993;72:2219-2223
11. Seregard S, Kock E. Prognostic indicators following enucleation for posterior uveal melanoma. A multivariate analysis of long-term survival with minimized loss to follow-up. Acta Ophthalmol. Scand. 1995;73:340-344
12. Rajpal S, Moore R, Karakousis CP. Survival in metastatic ocular melanoma. Cancer 1983;52:334-336
13. Bedikian AY, Legha SS, Mavligit G, et al. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer 1995;76:1665-1670
14. Alexander H, Bartlett D, Fraker D, et al. Regional treatment strategies for unresectable primary or metastatic cancer confined to the liver. In Vita VD, Hellman S, Rosenberg S, editors, Cancer: Principles and Practice of Oncology Philadelphia, Lippincott, 1996;
15. Van Ijken MG, van Etten B, de Wilt JH, et al. Tumor necrosis factor-alpha augments tumor effects in isolated hepatic perfusion with melphalan in a rat sarcoma model. J. Immunother. 2000;23:449-455
16. Lang H, Thyen A, Nadalin S, et al. Isolated hyperthermic liver perfusion with high dose tumor necrosis factor alpha in pigs: an experimental study in preparation of clinical Use. Eur. Surg. Res. 2000;32:1-10
17. Gnant MF, Noll LA, Terrill RE, et al. Isolated hepatic perfusion for lapine liver metastases: impact of hyperthermia on permeability of tumor neovasculature. Surgery 1999;126:890-899
18. van Ijken MG, de Bruijn EA, de Boeck G, et al. Isolated hypoxic hepatic perfusion with tumor necrosis factor-alpha, melphalan, and mitomycin C using balloon catheter techniques: a pharmacokinetic study in pigs. Ann. Surg. 1998;228:763-770
19. Ausman R. Development of a technique for isolated perfusion of the liver. N. Y. State J. Med. 1961;61:3393-3397
20. Skibba JL, Quebbeman EJ. Tumoricidal effects and patient survival after hyperthermic liver perfusion. Arch. Surg. 1986;121:1266-1271
21. Aigner KR, Walther H, Tonn JC, et al. [Isolated liver perfusion in advanced metastases of colorectal cancers.] Onkologie 1984;7:13-21
22. Schwemmle K, Link KH, Rieck B. Rationale and indications for perfusion in liver tumors: current data. World J. Surg. 1987;11:534-540
23. Marinelli A, Vahrmeijer AL, van de Velde CJ. Phase I/II studies of isolated hepatic perfusion with mitomycin C or melphalan in patients with colorectal cancer hepatic metastases. Recent Results Cancer Res. 1998;147:83-94
24. Marinelli A, de Brauw LM, Beerman H, et al. Isolated liver perfusion with mitomycin C in the treatment of colorectal cancer metastases confined to the liver. Jpn. J. Clin. Oncol. 1996;26:341-350
25. Vahrmeijer AL, Van Der Eb MM, Van Dierendonck JH, et al. Delivery of anticancer drugs via isolated hepatic perfusion: a promising strategy in the treatment of irresectable liver metastases? Semin. Surg. Oncol. 1998;14:262-268
26. Hafstrom LR, Holmberg SB, Naredi PL, et al. Isolated hyperthermic liver perfusion with chemotherapy for liver malignancy. Surg. Oncol. 1994;3:103-108
27. Oldhafer KJ, Lang H, Frerker M, et al. First experience and technical aspects of isolated liver perfusion for extensive liver metastasis. Surgery 1998;123:622-631
28. Lindner P, Fjalling M, Hafstrom L, et al. Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia, tumour necrosis factor alpha and melphalan. Eur. J. Surg. Oncol. 1999;25:179-185
29. Alexander HR, Bartlett DL, Libutti SK, et al. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J. Clin. Oncol. 1998;16:1479-1489
30. Alexander HR, Libutti SK, Bartlett DL, et al. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin. Cancer Res. 2000;6:3062-3070
31. Alexander HR, Bartlett DL, Libutti SK. Current status of isolated hepatic perfusion with or without tumor necrosis factor for the treatment of unresectable cancers confined to liver. Oncologist 2000;5:416-424
32. Bartlett DL, Libutti SK, Figg WD, et al. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery 2001;129:176-187
33. Urano M, Ling C. Thermal enhancement of melphalan and oxaliplatin cytotoxicity in vitro. Int. J. Hyperthermia 2002;18:307-315
34. Larrivee B, Averill D. Melphalan resistance and photoaffinity labelling of P-glycoprotein in multidrug-resistant Chinese hamster ovary cell reversal of resistance by cyclosporin A and hyperthermia. Biochem. Pharmacol. 1999;58:291-302
35. Bates D, MacKillop W. The effect of hyperthermia on the uptake and cytotoxicity of melphalan in Chinese hamster ovary cells. Int. J. Radiat. Oncol. Biol. Phys. 1989;16:187-191
36. Bates D, Herritzy L, Loutfi A, et al. The effect of hyperthermia on the cytotoxicity of melphalan in Chinese hamster ovary cells. Cancer Lett. 1987;34:145-155
37. Borel Rinkes IH, de Vries MR, Jonker AM, et al. Isolated hepatic perfusion in the pig with TNF-alpha with and without melphalan. Br. J. Cancer 1997;75:1447-1453
38. Casara D, Rubello D, Pilati P. A simplified procedure for continuous intraoperative external monitoring of systemic leakage during isolated limb perfusion cancer therapy. Eur. J. Nucl. Med. 2001;28:1174
39. Gilmore IT, Marigold JH, Thompson RP. Half-life time or clearance of indocyanine green in patients with liver disease. Hepatogastroenterology. 1982;29:55-57
40. de Vries MR, Rinkes IH, van de Velde CJ, et al. Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: experimental studies in pigs and phase I data from humans. Recent Results Cancer Res. 1998;147:107-119
41. Hafstrom L, Naredi P. Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia TNF alpha and melphalan: Swedish experience. Recent Results Cancer Res. 1998;147:120-126